SBRT2015

Louie AV, Radioth Oncol 2015

Priority areas for research

QUALITY(ASSURANCE(

◦

Monitor(outcomes(of(SABR(in(community(practice,(as(well(as(salvage(surgery(due(

to(misclassification(of(benign(fibrosis(

◦

Establish(optimal(SABR(doses(for(central(tumors(

◦

Determine(safe(dose@toxicity(criteria(for(critical(normal(organs(

DIAGNOSTIC(MANAGEMENT(

•

Establish(the(role(of(biopsy(in(the(FDG@PET(era(in(different(global(populations

(

•

Determine( the( role( of( EBUS/EUS( for( staging( subgroups( of( FDG@PET( staged(

patients

(

SURVIVORSHIP(

•

Develop(SDM(modules(for(patients(with(ES@NSCLC

(

•

Explore(the(safety(and(role(of(surgical(or(re@SABR(salvage

(